Police reports detailing Seagen CEO’s arrest raise questions about biotech’s response
Seagen, the $22 billion company Siegall co-founded in 1997, said he had taken a leave of absence sixteen days after the incident.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
Roche anti-TIGIT cancer immunotherapy fails second clinical trial, raising doubts about drug class
A new biotech investment firm, headed by a pair of noteworthy VCs, seeks to ‘free the founders’
Pfizer to buy Biohaven for $11.6 billion, raising hopes for the broader biotech market
From burst bubble to medical marvel: How lipid nanoparticles became the future of gene therapy
All Coverage
advertisement
